% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Rehm:282428,
author = {M. Rehm and A. Jaensch and B. Schöttker$^*$ and U.
Mons$^*$ and H. Hahmann and W. Koenig and H. Brenner$^*$ and
D. Rothenbacher$^*$},
title = {{M}edical care and biomarker-based assessment of mortality
in two cohorts of patients with chronic coronary syndrome 10
years apart.},
journal = {BMC cardiovascular disorders},
volume = {23},
number = {1},
issn = {1471-2261},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2023-01755},
pages = {428},
year = {2023},
note = {#LA:C070#},
abstract = {This study aimed to describe the characteristics and
mortality of two cohorts of patients with chronic coronary
syndrome (CCS) recruited with identical study designs in the
same rehabilitation clinics but approximately 10 years
apart.The KAROLA cohorts included patients with CCS
participating in an inpatient cardiac rehabilitation
programme in Germany (KAROLA-I: years 1999/2000, KAROLA-II:
2009-2011). Blood samples and information on
sociodemographic factors, lifestyle, and medical treatment
were collected at baseline, at the end of rehabilitation,
and after one year of follow-up. A biomarker-based risk
model (ABC-CHD model) and Cox regression analysis were used
to evaluate cardiovascular (CV) and non-CV mortality risk.We
included 1130 patients from KAROLA-I (mean age 58.7 years,
$84.4\%$ men) and 860 from KAROLA-II (mean age 60.4 years,
$83.4\%$ men). Patients in the KAROLA-I cohort had
significantly higher concentrations of CV biomarkers and
fewer patients were taking CV medications, except for
statins. The biomarker-based ABC-CHD model provided a higher
estimate of CV death risk for patients in the KAROLA-I
cohort (median 3-year risk, $3.8\%)$ than for patients in
the KAROLA-II cohort (median 3-year risk, $2.7\%,$ p-value
for difference < 0.001). After 10 years of follow-up, 91
$(8.1\%)$ patients in KAROLA-I and 45 $(5.2\%)$ in KAROLA-II
had died from a CV event.Advances in disease management over
the past 20 years may have led to modest improvements in
pharmacological treatment during cardiac rehabilitation and
long-term outpatient care for patients with CCS. However,
modifiable risk factors such as obesity have increased in
the more recent cohort and should be targeted to further
improve the prognosis of these patients.},
keywords = {Biomarkers (Other) / Cardiac rehabilitation (Other) /
Chronic coronary syndrome (Other) / Mortality (Other) /
Pharmacological treatment (Other) / Risk factors (Other)},
cin = {C070 / C120 / HD01 / M050},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)M050-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37644408},
doi = {10.1186/s12872-023-03469-4},
url = {https://inrepo02.dkfz.de/record/282428},
}